A Tennessee overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
37.6% of Tennessee adults have obesity, according to the CDC's BRFSS prevalence estimates for 2023 1. We cite 2023 rather than 2024 because Tennessee's 2024 BRFSS value was never published, and we would rather name the data year than quietly present an older figure as current. For the same reason there is no modelled adult count on this page: multiplying a 2023 rate by a 2024 population would produce a number neither agency stands behind.
Tennessee is the unusual state on this list. Most state pages exist to explain an exclusion. This one exists to explain a real benefit — and then to be honest about the two groups the benefit does not reach.
TennCare covers Wegovy and Zepbound for obesity, with prior authorization, effective August 1, 2025. The change arrived as an emergency rule and was later codified, and both drugs sit on the preferred drug list as preferred agents 3. That places Tennessee among the small number of state Medicaid programs still covering GLP-1s for weight rather than diabetes alone.
Prior authorization means the coverage is real but conditional. Your prescriber submits clinical documentation before the first fill: the diagnosis and the clinical criteria the program requires, what has been tried already, and the plan for monitoring. Approvals are time-limited and renewed on evidence of continued benefit. In practice the delay is usually paperwork rather than medicine, and the fastest way through it is a prescriber who has the chart notes ready before submitting.
So the honest reading is that if you are a TennCare member who meets the criteria, your cheapest path is your own benefit, not us. We would rather say that than sell around it.
Two groups are left. The first is Tennesseans not on TennCare — commercially insured through an employer that excludes weight-management drugs, or uninsured entirely. The second is TennCare members whose prior authorization is denied or not renewed. For both, the practical question stops being coverage and becomes cash price, and that is the part of the market Astra is built for. Tennessee's Attorney General has also warned consumers about weight-loss drugs obtained outside a valid prescription and a reliable licensed pharmacy, which is worth reading before shopping on price alone 5.
For anyone in those two groups, here is the whole number, once.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
It is worth comparing that against a denied prior authorization rather than against a covered one. If your benefit pays, use your benefit.
Yes. Tennessee law allows licensed healthcare providers to establish a provider-patient relationship and treat patients through telehealth, with no prior in-person visit required, and it holds telehealth care to the same standard of professional practice as in-person care (Tenn. Code Ann. Section 63-1-155 4). The statute's definition covers both real-time audio-video visits and store-and-forward (asynchronous) technology. Rules for compounded medications such as semaglutide and tirzepatide are set separately — by federal law under FDA's Section 503A framework and by the Tennessee Board of Pharmacy 6 — and those rules have continued to change through 2025 and 2026 after FDA declared the brand-name shortages resolved. Prescriptions through Astra are issued by independent licensed providers and filled by licensed pharmacies; current state requirements are available from the Tennessee Board of Pharmacy 6.
Our provider group holds Tennessee licensure and our partner pharmacies are licensed to dispense into the state, so a patient in the rural western counties or on the Cumberland Plateau can be evaluated and treated at a Tennessee address without traveling to a metro specialty clinic.
Astra treats patients in Tennessee through state-licensed physicians.
City pages carry local access context — county figures, clinician supply, and what the local market charges — under the same sourcing rules as this page.
Yes, for obesity, with prior authorization, effective August 1, 2025. Both Wegovy and Zepbound are listed as preferred agents on the TennCare preferred drug list, so a member who meets the program's clinical criteria can be approved on an obesity indication rather than only a diabetes one. Approval is not automatic: your prescriber has to submit documentation first, and authorizations are time-limited.
Then coverage is not your route and cash price is. If you are commercially insured, check whether your plan-year drug list excludes weight-management drugs before assuming it does, and ask for the prior-authorization criteria if the drugs appear. If you are denied, uninsured, or excluded, the realistic options are a documented appeal, a manufacturer direct-pay program for the branded product, or a cash-pay physician-supervised program such as Astra's.
No, and that is deliberate. Astra charges one price in every state it serves, published once in the cost section above. There is no Tennessee price list, no regional surcharge, and no local discount.
Possibly, but only under federal compounding conditions. Since FDA declared the semaglutide shortage resolved in February 2025, a licensed compounding pharmacy generally may dispense compounded semaglutide only for an individual patient whose prescriber determines and documents that a change from the FDA-approved product produces a significant difference for that patient (Section 503A) — so eligibility is decided by a licensed provider after a clinical evaluation, and availability is not guaranteed. FDA also warns that salt forms such as semaglutide sodium or acetate should not be used in compounding, and Tennessee's Attorney General urges consumers to use only a valid prescription filled by a reliable licensed pharmacy.
No. Tenn. Code Ann. Section 63-1-155 allows a licensed provider to establish a provider-patient relationship through telehealth with no prior in-person visit, using either real-time audio-video or store-and-forward technology, and holds that care to the same standard of professional practice as in-person care.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.